A New Gene Therapy Trial For Hunter Syndrome (MPS II) Treatment Is Available

Homology Medicines have received clearance from Health Canada to initiate the juMPStart trial for HMI-203, a one-time, in vivo gene therapy candidate for the treatment of adults with Hunter Syndrome (MPS II).

If you are interested in knowing more, join Homology Medicines’ juMPStart clinical trial educational webinar:

Tuesday, September 20 at 8:00 p.m. ET

The webinar will review details about Homology’s

investigational gene therapy – HMI-203 – and the

ongoing Phase 1 juMPStart clinical trial for adults.

To RSVP, please email

patientadvocacy@homologymedicines.com

Read the report:

https://www.globenewswire.com/news-release/2022/08/15/2498571/0/en/Homology-Medicines-Reports-Second-Quarter-2022-Financial-Results-Recent-Highlights-and-Provides-Business-Update.html